HK

Hariom Kulshrestha

Active Director Director DIN 08037272
DIN 08037272 First appointment Dec 2017 Primary industry Business Services
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Dec 2017
Shareholding value •••• Premium profile

About Hariom Kulshrestha

Data last updated:

Hariom Kulshrestha is a Director at Ostic Pharma Private Limited (since 2017), Director at Foundation For Tuberculosis Malnutrition And Aids (since 2019) and Director at Ayurtech Innovations Private Limited (since 2024), and holds 1 more current directorship. The companies operate in Business Services, Non-Profit Organizations and Pharma. The 3 current companies with reported revenue have a combined latest revenue of ₹34.6 Lakh; the largest is Ostic Pharma Private Limited at ₹26.4 Lakh (FY 2025). Earlier, Hariom Kulshrestha was a Director at Nanotech Ayurveda Research Institute Private Limited (from 2018).

DIN 08037272
Primary Designation Director
Industry Business Services
First Appointment 29 Dec 2017
Oldest Company Age 11 yrs
Largest company Ostic Pharma Private Limited · ₹26.4 Lakh (FY 2025)
Combined revenue ₹34.6 Lakh across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ostic Pharma Private Limited U74999MH2015PTC269933
Director29 Dec 20172015₹26.4 Lakh (FY 2025)Active
Director17 Jan 20192019₹8 Lakh (FY 2025)Active
Ayurtech Innovations Private Limited U47720UP2024PTC213541
Director18 Dec 20242024₹16,600 (FY 2025)Active
Director27 May 20232023Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 Nov 20182018₹6,750 (FY 2019)Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Ostic Pharma Private Limited
Foundation For Tuberculosis Malnutrition And Aids
Nanotech Ayurveda Research Institute Private Limited
Ayurtech Innovations Private Limited
Premium access

Shareholding and investment profile for Hariom Kulshrestha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hariom Kulshrestha

Hariom Kulshrestha currently holds 4 directorships: Ostic Pharma Private Limited (Director, since 29 Dec 2017, revenue ₹26.4 Lakh (FY 2025)); Foundation For Tuberculosis Malnutrition And Aids (Director, since 17 Jan 2019, revenue ₹8 Lakh (FY 2025)); Ayurtech Innovations Private Limited (Director, since 18 Dec 2024, revenue ₹16,600 (FY 2025)); Shreshthatam Ayurveda Pharmaceutical Private Limited (Director, since 27 May 2023).

Hariom Kulshrestha was first appointed on 29 Dec 2017 as Director at Ostic Pharma Private Limited. The most recent appointment on record is 18 Dec 2024 at Ayurtech Innovations Private Limited.

The 3 current companies of Hariom Kulshrestha that report revenue have a combined latest revenue of ₹34.6 Lakh: Ostic Pharma Private Limited ₹26.4 Lakh (FY 2025); Foundation For Tuberculosis Malnutrition And Aids ₹8 Lakh (FY 2025); Ayurtech Innovations Private Limited ₹16,600 (FY 2025).

Hariom Kulshrestha held 1 earlier board appointment: Nanotech Ayurveda Research Institute Private Limited (Director, from 20 Nov 2018).

The current boards of Hariom Kulshrestha's companies include Kusum Saini (Ostic Pharma Private Limited), Vinay Saini (Ostic Pharma Private Limited), Namita Kulshrestha (Ayurtech Innovations Private Limited), Bharat Kumar (Shreshthatam Ayurveda Pharmaceutical Private Limited), Sudarshan Kumar (Shreshthatam Ayurveda Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available